BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $67.00 price target on Silence Therapeutics (NASDAQ: SLN).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE